97 related articles for article (PubMed ID: 7811262)
21. Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity.
Higashi S; Miyazaki K
J Biol Chem; 2003 Apr; 278(16):14020-8. PubMed ID: 12586836
[TBL] [Abstract][Full Text] [Related]
22. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues.
Yamada T; Yoshiyama Y; Sato H; Seiki M; Shinagawa A; Takahashi M
Acta Neuropathol; 1995; 90(5):421-4. PubMed ID: 8560972
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the importance of weakly bound water for matrix metalloproteinase activity.
Willenbrock F; Knight CG; Murphy G; Phillips IR; Brocklehurst K
Biochemistry; 1995 Sep; 34(37):12012-8. PubMed ID: 7547939
[TBL] [Abstract][Full Text] [Related]
24. The processing of Alzheimer A4/beta-amyloid protein precursor: identification of a human brain metallopeptidase which cleaves -Lys-Leu- in a model peptide.
McDermott JR; Gibson AM
Biochem Biophys Res Commun; 1991 Sep; 179(3):1148-54. PubMed ID: 1930159
[TBL] [Abstract][Full Text] [Related]
25. Native type I collagen is not a substrate for MMP2 (gelatinase A).
Seltzre JL; Eisen AZ
J Invest Dermatol; 1999 Jun; 112(6):993-4. PubMed ID: 10383752
[No Abstract] [Full Text] [Related]
26. The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein.
Eble JA; Ries A; Lichy A; Mann K; Stanton H; Gavrilovic J; Murphy G; Kühn K
J Biol Chem; 1996 Nov; 271(48):30964-70. PubMed ID: 8940084
[TBL] [Abstract][Full Text] [Related]
27. Enzymatic processing by MMP-2 and MMP-9 of wild-type and mutated mouse β-dystroglycan.
Sbardella D; Inzitari R; Iavarone F; Gioia M; Marini S; Sciandra F; Castagnola M; Van den Steen PE; Opdenakker G; Giardina B; Brancaccio A; Coletta M; Bozzi M
IUBMB Life; 2012 Dec; 64(12):988-94. PubMed ID: 23129308
[TBL] [Abstract][Full Text] [Related]
28. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease.
Gowing E; Roher AE; Woods AS; Cotter RJ; Chaney M; Little SP; Ball MJ
J Biol Chem; 1994 Apr; 269(15):10987-90. PubMed ID: 8157623
[TBL] [Abstract][Full Text] [Related]
29. Lefty peptides, derived by MMP2 cleavage, act as a new class of gelatinase A inhibitor.
Naidu DG; Tang M; Tabibzadeh S
Front Biosci; 2008 May; 13():7193-201. PubMed ID: 18508727
[TBL] [Abstract][Full Text] [Related]
30. Functional requirement for human pitrilysin metallopeptidase 1 arginine 183, mutated in amyloidogenic neuropathy.
Smith-Carpenter JE; Alper BJ
Protein Sci; 2018 Apr; 27(4):861-873. PubMed ID: 29383861
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A.
Libson AM; Gittis AG; Collier IE; Marmer BL; Goldberg GI; Lattman EE
Nat Struct Biol; 1995 Nov; 2(11):938-42. PubMed ID: 7583664
[TBL] [Abstract][Full Text] [Related]
32. Altered cell-matrix associated ADAM proteins in Alzheimer disease.
Gerst JL; Raina AK; Pirim I; McShea A; Harris PL; Siedlak SL; Takeda A; Petersen RB; Smith MA
J Neurosci Res; 2000 Mar; 59(5):680-4. PubMed ID: 10686596
[TBL] [Abstract][Full Text] [Related]
33. Structural identification and proteolytic effects of the hatching enzyme from starfish Asterias amurensis.
Li ZJ; Kim SM
Protein Pept Lett; 2014 Jul; 21(7):631-8. PubMed ID: 24559163
[TBL] [Abstract][Full Text] [Related]
34. Effects of Cerebrospinal Fluids from Alzheimer and Non-Alzheimer Patients on Neurons-Astrocytes-Microglia Co-Culture.
Iemmolo M; Bivona G; Piccoli T; Nicosia A; Schiera G; Di Liegro CM; Di Pietra F; Ghersi G
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473758
[TBL] [Abstract][Full Text] [Related]
35. Consequences of Amyloid-β Deficiency for the Liver.
Buniatian GH; Schwinghammer U; Tremmel R; Cynis H; Weiss TS; Weiskirchen R; Lauschke VM; Youhanna S; Ramos I; Valcarcel M; Seferyan T; Rahfeld JU; Rieckmann V; Klein K; Buadze M; Weber V; Kolak V; Gebhardt R; Friedman SL; Müller UC; Schwab M; Danielyan L
Adv Sci (Weinh); 2024 May; 11(18):e2307734. PubMed ID: 38430535
[TBL] [Abstract][Full Text] [Related]
36. N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer's pathophysiology.
Rostagno A; Cabrera E; Lashley T; Ghiso J
Transl Neurodegener; 2022 Jun; 11(1):30. PubMed ID: 35641972
[TBL] [Abstract][Full Text] [Related]
37. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives.
Behl T; Kaur G; Sehgal A; Bhardwaj S; Singh S; Buhas C; Judea-Pusta C; Uivarosan D; Munteanu MA; Bungau S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573368
[TBL] [Abstract][Full Text] [Related]
38. Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes.
Milardi D; Gazit E; Radford SE; Xu Y; Gallardo RU; Caflisch A; Westermark GT; Westermark P; Rosa C; Ramamoorthy A
Chem Rev; 2021 Feb; 121(3):1845-1893. PubMed ID: 33427465
[TBL] [Abstract][Full Text] [Related]
39. Engineering of fluorescent or photoactive Trojan probes for detection and eradication of β-Amyloids.
Aziz AA; Siddiqui RA; Amtul Z
Drug Deliv; 2020 Dec; 27(1):917-926. PubMed ID: 32597244
[TBL] [Abstract][Full Text] [Related]
40. Amyloid beta peptide-degrading microbial enzymes and its implication in drug design.
Dhanavade MJ; Sonawane KD
3 Biotech; 2020 Jun; 10(6):247. PubMed ID: 32411571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
